180 related articles for article (PubMed ID: 18598097)
1. Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results.
Van Campenhout H; Marbaix S; Derde MP; Annemans L
Clin Drug Investig; 2008; 28(8):509-21. PubMed ID: 18598097
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
5. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
6. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis.
Greene RE; Mauskopf J; Roberts CS; Zyczynski T; Schlamm HT
Am J Health Syst Pharm; 2007 Dec; 64(24):2561-8. PubMed ID: 18056944
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
11. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Harrington R; Lee E; Yang H; Wei J; Messali A; Azie N; Wu EQ; Spalding J
Adv Ther; 2017 Jan; 34(1):207-220. PubMed ID: 27913989
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
Luong ML; Husain S; Rotstein C
Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
[TBL] [Abstract][Full Text] [Related]
15. Economic effects of aspergillosis management in high-risk patients.
Leather H
Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
[TBL] [Abstract][Full Text] [Related]
16. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
[TBL] [Abstract][Full Text] [Related]
17. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
19. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of voriconazole.
Rubio-Terrés C; Grau S
Expert Opin Pharmacother; 2010 Apr; 11(6):877-87. PubMed ID: 20201729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
